Microbial Adjuncts for Food Allergen Immunotherapy
Purpose of Review
Food allergen immunotherapy may benefit from adjunct therapies to enhance safety and efficacy. We review preclinical studies investigating the effects of probiotics and other microbial-based interventions on oral tolerance, describe the human clinical trial evidence thus far for microbial adjuncts, and discuss steps for translating research findings in this area to clinical therapy.
Murine studies support that microbial-based interventions confer protection against sensitization and may augment treatment efficacy for food allergy. Microbial adjunct therapies can promote regulatory T cells and modulate Th1 vs. Th2 responses. There is a wide array of novel modalities utilizing microbial components. Ongoing efforts are focused on translating preclinical data into potential treatments.
Probiotics, prebiotics, and microbial components have all been examined as microbial adjunct therapies in murine models of food allergy. The effects of probiotics appear to be strain-specific. Prebiotics and bacterial components are innovative modalities to modulate oral tolerance. Better characterization of dysbiosis in human cohorts with food allergy, deeper mechanistic understanding of microbial adjunct therapies, safety evaluation, and careful clinical trial design will be crucial for the development of microbial adjuncts for food allergen immunotherapy. Microbial adjunct therapies have the potential to enhance the efficacy, safety, and durability of food allergen immunotherapy.
KeywordsFood allergy Immunotherapy Microbiome Microbiota Microbial adjunct Peanut allergy Probiotics Prebiotics Oral tolerance
Compliance with Ethical Standards
Conflict of Interest
Dr. Bunyavanich reports grants from the National Institutes of Health, during the conduct of the study. Dr. Hsi-en Ho declares no conflicts of interest relevant to this manuscript.
Human and Animal Rights and Informed Consent
This article does not contain any studies with human or animal subjects performed by any of the authors.
Papers of particular interest, published recently, have been highlighted as: • Of importance •• Of major importance
- 2.Osborne NJ, Koplin JJ, Martin PE, Gurrin LC, Lowe AJ, Matheson MC, et al. Prevalence of challenge-proven IgE-mediated food allergy using population-based sampling and predetermined challenge criteria in infants. J Allergy Clin Immunol. 2011;127(3):668–76 e1-2. https://doi.org/10.1016/j.jaci.2011.01.039.CrossRefPubMedGoogle Scholar
- 3.Nowak-Wegrzyn A, Wood RA, Nadeau KC, Pongracic JA, Henning AK, Lindblad RW, et al. Multicenter, randomized, double-blind, placebo-controlled clinical trial of vital wheat gluten oral immunotherapy. J Allergy Clin Immunol. 2018.Google Scholar
- 4.•• Investigators PGoC, Vickery BP, Vereda A, Casale TB, Beyer K, du Toit G, et al. AR101 oral immunotherapy for peanut allergy. N Engl J Med. 2018;379(21):1991–2001. This study is the first large scale phase 3 randomized, controlled trial for peanut OIT. In the age 4 to 17 years cohort, 67.2% of active treated group, as compared to 4.0% of the placebo group, were able to ingest 600 mg or more of peanut protein without symptoms. Efficacy was not shown in participants age 18 years or older. Adverse events during treatment were observed in more than 95% of the participants age 4 to 17 years. The study highlights the efficacy and current limitations of OIT. https://doi.org/10.1056/NEJMoa1812856.CrossRefGoogle Scholar
- 6.Anagnostou K, Islam S, King Y, Foley L, Pasea L, Bond S, et al. Assessing the efficacy of oral immunotherapy for the desensitisation of peanut allergy in children (STOP II): a phase 2 randomised controlled trial. Lancet. 2014;383(9925):1297–304. https://doi.org/10.1016/S0140-6736(13)62301-6.CrossRefGoogle Scholar
- 10.Zhao W, Ho HE, Bunyavanich S. The gut microbiome in food allergy. Ann Allergy Asthma Immunol. 2018.Google Scholar
- 15.Cassani B, Villablanca EJ, Quintana FJ, Love PE, Lacy-Hulbert A, Blaner WS, et al. Gut-tropic T cells that express integrin alpha4beta7 and CCR9 are required for induction of oral immune tolerance in mice. Gastroenterology. 2011;141(6):2109–18. https://doi.org/10.1053/j.gastro.2011.09.015.CrossRefPubMedPubMedCentralGoogle Scholar
- 17.Lee JB, Chen CY, Liu B, Mugge L, Angkasekwinai P, Facchinetti V, et al. IL-25 and CD4(+) TH2 cells enhance type 2 innate lymphoid cell-derived IL-13 production, which promotes IgE-mediated experimental food allergy. J Allergy Clin Immunol. 2016;137(4):1216–25 e5. https://doi.org/10.1016/j.jaci.2015.09.019.CrossRefGoogle Scholar
- 22.Kulis M, Saba K, Kim EH, Bird JA, Kamilaris N, Vickery BP, et al. Increased peanut-specific IgA levels in saliva correlate with food challenge outcomes after peanut sublingual immunotherapy. J Allergy Clin Immunol. 2012;129(4):1159–62. https://doi.org/10.1016/j.jaci.2011.11.045.CrossRefGoogle Scholar
- 24.Varshney P, Jones SM, Scurlock AM, Perry TT, Kemper A, Steele P, et al. A randomized controlled study of peanut oral immunotherapy: clinical desensitization and modulation of the allergic response. J Allergy Clin Immunol. 2011;127(3):654–60. https://doi.org/10.1016/j.jaci.2010.12.1111.CrossRefGoogle Scholar
- 26.• Syed A, Garcia MA, Lyu SC, Bucayu R, Kohli A, Ishida S. et al.Peanut oral immunotherapy results in increased antigen-induced regulatory T-cell function and hypomethylation of forkhead box protein 3 (FOXP3). J Allergy Clin Immunol. 2014;133(2):500–10. This study evaluated the immune profile of subjects who underwent peanut OIT. After completion of peanut OIT and 3 months of therapy withdrawl, T-cell function and demethylation of FOXP3 CpG sites in antigen-induced Treg cells were signficantly different between peanut-tolerant versus nontolerant subjects. The results implicated Treg cells as a part of the mechanisms of actions of OIT. https://doi.org/10.1016/j.jaci.2013.12.1037.CrossRefGoogle Scholar
- 36.Huang YJ, Marsland BJ, Bunyavanich S, O'Mahony L, Leung DY, Muraro A, et al. The microbiome in allergic disease: current understanding and future opportunities-2017 PRACTALL document of the American Academy of Allergy, Asthma & Immunology and the European Academy of Allergy and Clinical Immunology. J Allergy Clin Immunol. 2017;139(4):1099–110. https://doi.org/10.1016/j.jaci.2017.02.007.CrossRefPubMedPubMedCentralGoogle Scholar
- 39.Rodriguez B, Prioult G, Hacini-Rachinel F, Moine D, Bruttin A, Ngom-Bru C, et al. Infant gut microbiota is protective against cow's milk allergy in mice despite immature ileal T-cell response. FEMS Microbiol Ecol. 2012;79(1):192–202. https://doi.org/10.1111/j.1574-6941.2011.01207.x.CrossRefGoogle Scholar
- 42.•• Narushima S, Sugiura Y, Oshima K, Atarashi K, Hattori M, Suematsu M. et al.Characterization of the 17 strains of regulatory T cell-inducing human-derived Clostridia. Gut Microbes. 2014;5(3):333–9. In line with the concept of probiotics, this group isolated 17 strains of Clostridia from heathy human fecal samples that are capable of attenuating the symptoms of OVA-induced allergic diarrhea when introduced in mice. These 17 Clostridia strains significantly increased the number and function of colonic Treg cells in colonized mice. https://doi.org/10.4161/gmic.28572.CrossRefGoogle Scholar
- 46.•• Tan J, McKenzie C, Vuillermin PJ, Goverse G, Vinuesa CG, Mebius RE, et al. Dietary fiber and bacterial SCFA enhance oral tolerance and protect against food allergy through diverse cellular pathways. Cell Rep. 2016;15(12):2809–24. In line with the concept of prebiotics, the group demonstrated that a high-fiber diet in mice was protective for food allergy in a peanut sensitization model. High-fiber feeding was shown to reshape the gut microbiota and increase the release of select short-chain fatty acids, leading to enhanced tolerogenic CD103+ DC activities in a vitamin A-dependent manner. https://doi.org/10.1016/j.celrep.2016.05.047.CrossRefPubMedGoogle Scholar
- 49.Kulis M, Gorentla B, Burks AW, Zhong XP. Type B CpG oligodeoxynucleotides induce Th1 responses to peanut antigens: modulation of sensitization and utility in a truncated immunotherapy regimen in mice. Mol Nutr Food Res. 2013;57(5):906–15. https://doi.org/10.1002/mnfr.201200410.CrossRefPubMedGoogle Scholar
- 50.Soos TJ, Li L, Graver K, Schiding J, Xenos A, Chen D, et al. Glucopyranosyl lipid A (GLA) a Toll-like receptor 4 (TLR4) agonist for use as an adjuvant in combination with peanut allergen immunotherapy. J Allergy Clin Immunol. 2016;137(2):AB129. https://doi.org/10.1016/j.jaci.2015.12.555.CrossRefGoogle Scholar
- 51.• Kim JH, Jeun EJ, Hong CP, Kim SH, Jang MS, Lee EJ, et al. Extracellular vesicle-derived protein from Bifidobacterium longum alleviates food allergy through mast cell suppression. J Allergy Clin Immunol. 2016;137(2):507–16 e8. This group identified an extracellular vesicle-derived protein from Bifidobacterium longum that is capable of suppressing mast cell response through mast cell-specific apoptosis. Injection of this bacterial protein reduced allergic diarrhea symptoms in an egg OVA sensitization murine model. https://doi.org/10.1016/j.jaci.2015.08.016.PubMedGoogle Scholar
- 52.Matteoli G, Mazzini E, Iliev ID, Mileti E, Fallarino F, Puccetti P, et al. Gut CD103+ dendritic cells express indoleamine 2,3-dioxygenase which influences T regulatory/T effector cell balance and oral tolerance induction. Gut. 2010;59(5):595–604. https://doi.org/10.1136/gut.2009.185108.CrossRefGoogle Scholar
- 61.Patel P, Holdich T, Fischer von Weikersthal-Drachenberg KJ, Huber B. Efficacy of a short course of specific immunotherapy in patients with allergic rhinoconjunctivitis to ragweed pollen. J Allergy Clin Immunol. 2014;133(1):121–9 e1–2. https://doi.org/10.1016/j.jaci.2013.05.032.CrossRefPubMedGoogle Scholar
- 63.• Tang ML, Ponsonby AL, Orsini F, Tey D, Robinson M, Su EL, et al. Administration of a probiotic with peanut oral immunotherapy: a randomized trial. J Allergy Clin Immunol. 2015;135(3):737–44 e8. This was the first placebo-controlled randomized peanut OIT trial utilizing probiotic (Lactobacillus rhamnosus GG) as adjunct therapy. A high prevalence of sustained unresponsiveness to peanut (82.1%) was reported in the treated children; however, the specific contribution of probiotics was unclear due to the lack of an OIT-only treatment arm. https://doi.org/10.1016/j.jaci.2014.11.034.CrossRefGoogle Scholar
- 64.Hsiao KC, Ponsonby AL, Axelrad C, Pitkin S, Tang MLK, Team PS. Long-term clinical and immunological effects of probiotic and peanut oral immunotherapy after treatment cessation: 4-year follow-up of a randomised, double-blind, placebo-controlled trial. Lancet Child Adolesc Health. 2017;1(2):97–105. https://doi.org/10.1016/S2352-4642(17)30041-X.CrossRefPubMedGoogle Scholar
- 66.Mileti E, Matteoli G, Iliev ID, Rescigno M. Comparison of the immunomodulatory properties of three probiotic strains of Lactobacilli using complex culture systems: prediction for in vivo efficacy. PLoS One. 2009;4(9):e7056. https://doi.org/10.1371/journal.pone.0007056.CrossRefPubMedPubMedCentralGoogle Scholar